Rivaroxaban Versus Warfarin in Acute Ischemic Stroke With Atrial Fibrillation
A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 195 participants.
Also called NCT02042534
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose treatment
- Phase
- Phase 2
- Enrolled
- 195 participants
- Sponsor
- Registry
-
NCT02042534
-
- Other papers using this trial's data
- Rivaroxaban vs Warfarin Sodium in the Ultra-Early Period After Atrial Fibrillation-Related Mild Ischemic Stroke: A Randomized Clinical Trial
- Start date
- (registry gives no type)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- South Korea
- Registry status
- Completed
Technical summary
Registry record NCT02042534. Randomized; no masking; primary purpose treatment. Start 2014-01 (registry gives no type); primary completion 2015-12 (actual). Results posted on 2017-02-08.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Rivaroxaban Versus Warfarin in Acute Ischemic Stroke With Atrial Fibrillation
- Acronym
- TripleAXEL
- Condition
- Ischemic Stroke
- Condition
- Transient Ischemic Attack
- Intervention (Drug)
- Rivaroxaban
- Intervention (Drug)
- Warfarin
- Lead sponsor
- Asan Medical Center
- Collaborator
- Bayer
Record details
- Record id
cardio:ct-nct02042534- Content hash
cdfbe35da906d1b5a340108e831f8bf8964cab044ed4c15f5d7cb759a0b2cb69